Results 71 to 80 of about 3,073 (170)

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa

Antibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group   +24 more
doaj   +1 more source

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

Antibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China

BMC Microbiology
Purpose This nine-year (2016–2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on ...
Yungang Han, Qi Wang, Hao Chen, Zheng Li, Yali Wang, Yue Zhao, Shuang Xia, Wenyi He, Xiangjie Qiu, Huihui Chen, Jing Li, Yingying Yuan, Wei Wang   +12 more
doaj   +1 more source

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

BMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Timothy B. Doyle, Mariana Castanheira   +4 more
doaj   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +2 more sources

Outline of Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacteriaceae

International Journal of Pharmaceutical Sciences Review and Research, 2023
Dr. Kush Nimron, Dr. Johncy Nathasha
openaire   +1 more source

Treatment of Post-Neurosurgical Ventriculitis and Scalp Infection Caused by Klebsiella pneumoniae Carbapenemase and New Delhi Metallo-β-Lactamase Co-Producing Carbapenem-Resistant Klebsiella pneumoniae: A Case Report. [PDF]

Cureus
Ma XR, Chen SY, Wu RH, Li Q, Zhang JM, Ni M, Shen F.   +6 more
europepmc   +1 more source